Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sun Pharmaceutical Industries
- 30 Sep 2016 Status changed from active, no longer recruiting to completed.
- 20 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Mar 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2013-01-003289).